Response to bortezomib therapy for multiple myeloma (MM) in actual clinical practice: Preliminary effectiveness findings of an international observational study

被引：0
|
作者：
Delforge, Michel [1 ]
Katodritou, Eirini [2 ]
Zervas, Konstantinos [2 ]
Sargin, Deniz [3 ]
Hulin, Cyrille [4 ]
Linderholm, Mats [5 ]
Verrou, Evgenia [2 ]
Poon, Vicki [6 ]
Dhawan, Ravinder [6 ]
机构：
[1] Univ Hosp Leuven, Dept Hematol, Louvain, Belgium
[2] Theagenion Canc Ctr, Dept Hematol, Thessaloniki, Greece
[3] Istanbul Univ, Dept Internal Med, Div Hematol, Istanbul, Turkey
[4] Univ Nancy Brabois, Ctr Hosp, Vandoeuvre Les Nancy, France
[5] Linkoping Univ Hosp, Dept Haematol, S-58185 Linkoping, Sweden
[6] Johnson & Johnson, Raritan, NJ USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4837.4837
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4837
引用
收藏
页码：284B / 284B
页数：1
相关论文
共 50 条
  • [21] The role of lenalidomide-dexamethasone therapy in elderly patients with multiple myeloma in clinical practice: comparison with bortezomib-based therapy
    Kwon, Jihyun
    Lee, Yong-Pyo
    Park, Hee Sue
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S101 - S101
  • [22] Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
    Kumar, S. K.
    Lee, J. H.
    Lahuerta, J. J.
    Morgan, G.
    Richardson, P. G.
    Crowley, J.
    Haessler, J.
    Feather, J.
    Hoering, A.
    Moreau, P.
    LeLeu, X.
    Hulin, C.
    Klein, S. K.
    Sonneveld, P.
    Siegel, D.
    Blade, J.
    Goldschmidt, H.
    Jagannath, S.
    Miguel, J. S.
    Orlowski, R.
    Palumbo, A.
    Sezer, O.
    Rajkumar, S. V.
    Durie, B. G. M.
    LEUKEMIA, 2012, 26 (01) : 149 - 157
  • [23] Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
    S K Kumar
    J H Lee
    J J Lahuerta
    G Morgan
    P G Richardson
    J Crowley
    J Haessler
    J Feather
    A Hoering
    P Moreau
    X LeLeu
    C Hulin
    S K Klein
    P Sonneveld
    D Siegel
    J Bladé
    H Goldschmidt
    S Jagannath
    J S Miguel
    R Orlowski
    A Palumbo
    O Sezer
    S V Rajkumar
    B G M Durie
    Leukemia, 2012, 26 : 149 - 157
  • [24] BORTEZOMIB (VEL) BASED REGIMENS IN MULTIPLE MYELOMA (MM) PATIENTS WITH RENAL IMPAIRMENT (RI): A PRELIMINARY RETROSPECTIVE ITALIAN MULTICENTER STUDY
    Gentile, M.
    Ciolli, S.
    Petrucci, M. T.
    Galimberti, S.
    Mele, G.
    Casulli, A. F.
    Mannina, D.
    Piro, E.
    Morabito, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 84 - 84
  • [25] Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study
    Gentile, Massimo
    Ciolli, Stefania
    Petrucci, Maria Teresa
    Galimberti, Sara
    Mele, Giuseppe
    Casulli, Antonio Francesco
    Mannina, Donato
    Piro, Eugenio
    Pinotti, Graziella
    Palmieri, Salvatore
    Catalano, Lucio
    Callea, Vincenzo
    Offidani, Massimo
    Musto, Pellegrino
    Bringhen, Sara
    Baldini, Luca
    Tosi, Patrizia
    Di Raimondo, Francesco
    Boccadoro, Mario
    Palumbo, Antonio
    Cavo, Michele
    Morabito, Fortunato
    BLOOD, 2008, 112 (11) : 1260 - 1261
  • [26] Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): Preliminary results of a phase 1/2 study
    Richardson, Paul
    Jagannath, Sundar
    Raje, Noopur
    Jakubowiak, Andrzej
    Lonial, Sagar
    Avigan, David
    Ghobrial, Irene
    Schlossman, Robert
    Mazumder, Amitabha
    Munshi, Nikhil
    Joyce, Robin
    Doss, Deborah
    Warren, Diane
    Hayes, Stephen
    Giove, Lawrence
    Kaster, S.
    Delaney, Carol
    Lauria, Marisa
    Mitsiades, Constantine
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth
    BLOOD, 2007, 110 (11) : 63A - 63A
  • [27] Phase II study of total therapy 3 (TT3) with added bortezomib (V) for multiple myeloma (MM)
    Barlogie, B.
    Anaissie, E.
    Shaughnessy, J. D., Jr.
    van Rhee, F.
    Hollmig, K.
    Pineda-Roman, M.
    Mohiuddin, A.
    Zangari, M.
    Tricot, G.
    Crowley, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] BORTEZOMIB-BASED THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-WORLD MEDICAL PRACTICE: FINAL DATA FROM THE INTERNATIONAL, OBSERVATIONAL EVOBS STUDY
    Terpos, E.
    Katodritou, E.
    de la Rubia, J.
    Hungria, V.
    Hulin, C.
    Roussou, M.
    Delforge, M.
    Bries, G.
    Stoppa, A.
    Aagesen, J.
    Sargin, D.
    Belch, A.
    Diels, J.
    Chirita, O.
    Olie, R.
    Robinson, D., Jr.
    Dhawan, R.
    Ganguly, R.
    Potamianou, A.
    van de Velde, H.
    Dimopoulos, M.
    HAEMATOLOGICA, 2013, 98 : 601 - 601
  • [29] Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide
    H M Prince
    B Schenkel
    L Mileshkin
    Leukemia, 2007, 21 : 818 - 820
  • [30] PRELIMINARY STUDY OF CLINICAL VALIDATION OF THE RESPONSE CRITERIA PROPOSED BY THE INTERGROUPE FRANCOPHONE OF MYELOMA FOR PATIENTS WITH MULTIPLE MYELOMA
    Melero Lopez, D.
    Liria Gonzalez, I
    Barbosa de Carvalho, N.
    Moreira Pais, T.
    Tejedor Diaz, C.
    Puerta Fonolla, P.
    HAEMATOLOGICA, 2019, 104 : 400 - 400
12345